녹십자

006280KOSPI의약품 제조업

45.1 / 100

Reference Date: 2026-06-10

Financial Score12.0 / 40

News Sentiment18.1 / 25

Momentum5.0 / 20

Disclosure10.0 / 15

AI Analysis: the high debt ratio poses financial risk, ROE is below the industry average. Declined 9.7% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

LG Chem is a pharmaceutical company specializing in blood products and vaccines, with 2025 consolidated sales reaching 19.9 trillion won, a 18.54% increase from the previous year. Key products include ALYGLO, successfully launched in the U.S. market, the WHO-certified chickenpox vaccine 'BariCella', and the hemophilia treatment 'Greenjin E' approved in China. The company is focused on global expansion through strategic products and innovation.

Number of Employees

2,351people

Average Salary

73.1M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 11.934.0Point

PBR

1.03Industry Average 0.892.5Point

Higher than industry avg (caution)

ROE

-2.07Industry Average 4.010.0Point

Well below industry avg

Debt Ratio

30.91Industry Average 12.430.0Point

2.5x industry avg (risky)

Trend 2023~20255.5 / 10 points

Revenue Growth Rate

2.5 / 3

Avg ▲10.9% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲54.3% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -2.1% (declining, 3yr)

Detailed News Sentiment

62 totalPositive 40Neutral 20Negative 2Average Sentiment Score 72.3

Positive
‘글로벌 빅파마’ 릴리, K-바이오에 끝없는 R&D 러브콜
글로벌 제약업체 릴리의 대규모 투자로 녹십자의 R&D 역량 강화 기대
Positive
한미·오스코텍 등 대형계약…K바이오 기술수출 13조 육박
녹십자의 기술수출 계약 증가로 인해 K바이오 산업의 성장이 기대되며, 시장에서 긍정적인 반응을 보임.
Positive
KC코트렐·GC지놈, 최대주주 지분 보호예수 해제
녹십자 최대주주 지분의 보호예수 해제로 인해 시장에서의 유동성이 증가하여 긍정적 영향 예상.

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 123,300Won52-week high 180,30052-week low 123,300

1-month return1.0Point

1m -9.74% (falling)

Volume trend3.0Point

Volume flat

Detailed Disclosure

3 totalPositive 0Neutral 3Negative 0

Neutral기업지배구조보고서공시2026-06-01
Neutral주요사항보고서(타법인주식및출자증권양도결정)2026-05-27
Neutral분기보고서 (2026.03)2026-05-15